Polypid News Today

HC Wainwright reaffirmed their buy rating on shares of PolyPid (NASDAQ:PYPD – Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $14.00 target price on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings […]

HC Wainwright reiterated their buy rating on shares of PolyPid (NASDAQ:PYPD – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a $14.00 target price on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, […]

PolyPid (NASDAQ:PYPD – Get Free Report) and LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings. Earnings and Valuation This table compares PolyPid and […]

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash ...

PolyPid (NASDAQ:PYPD – Get Free Report) and Assure (NASDAQ:IONM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings. Risk and Volatility PolyPid has a beta of 1.45, […]

PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the recipient of a significant decline in short interest in November. As of November 15th, there was short interest totalling 1,000 shares, a decline of 68.8% from the October 31st total of 3,200 shares. Currently, 0.1% of the company’s shares are short sold. Based on an average […]

PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totalling 1,500 shares, a drop of 88.7% from the August 31st total of 13,300 shares. Based on an average trading volume of 5,500 shares, the short-interest ratio is […]

PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the target of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 13,300 shares, a decrease of 81.3% from the August 15th total of 71,100 shares. Based on an average daily trading volume, of 66,000 shares, […]

PolyPid (NASDAQ:PYPD – Get Free Report) and Merit Medical Systems (NASDAQ:MMSI – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation. Profitability This table compares PolyPid and Merit Medical […]

Reached Agreement with U.S. FDA on Design of SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Resumed Recruitment into SHIELD II Phase 3 Trial in Late June 2023 Total of 20 centers in U.S., Europe and Israel Expected to be Opened by End of Current Quarter Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Aug. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Compan...